Covered recipient · General Payments record
SONYA L MILES
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner
General Payments · PY2021–2024
$853.36
- Reported across 33 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $428.30 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $125.00 | 1 |
| Lilly USA, LLC | $88.02 | 4 |
| ABBVIE INC. | $32.91 | 1 |
| Novo Nordisk AS | $29.88 | 2 |
| DEXCOM, INC. | $28.98 | 1 |
| Ultragenyx Pharmaceutical Inc. | $27.41 | 1 |
| Indivior Inc. | $22.57 | 1 |
| Kyowa Kirin, Inc. | $21.26 | 1 |
| Exact Sciences Corporation | $20.10 | 1 |
| ITI, Inc. | $16.09 | 1 |
| Acerta Pharma LLC | $16.08 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $32.91 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107661110 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.08 | 06/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104297636 | CMS |
| Dexcom, Inc. | $28.98 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153387312 | CMS |
| Exact Sciences Corporation | $20.10 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114497265 | CMS |
| GlaxoSmithKline, LLC. | $125.00 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116246914 | CMS |
| Indivior Inc. | $22.57 | 11/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144563319 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.09 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143551799 | CMS |
| Kyowa Kirin, Inc. | $21.26 | 12/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127056037 | CMS |
| Lilly USA, LLC | $21.77 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135890382 | CMS |
| Lilly USA, LLC | $16.47 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135965452 | CMS |
| Lilly USA, LLC | $31.49 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135866514 | CMS |
| Lilly USA, LLC | $18.29 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135942186 | CMS |
| Novo Nordisk Inc | $14.13 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100286330 | CMS |
| Novo Nordisk Inc | $15.75 | 08/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100347700 | CMS |
| Ultragenyx Pharmaceutical Inc. | $27.41 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153281800 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.